Free Trial

Journey Medical (DERM) Competitors

Journey Medical logo
$7.10 +0.06 (+0.85%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DERM vs. KALV, EOLS, SANA, UPB, SAGE, ALT, TNGX, KROS, RLAY, and AUTL

Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry.

Journey Medical vs. Its Competitors

KalVista Pharmaceuticals (NASDAQ:KALV) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

KalVista Pharmaceuticals has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

In the previous week, KalVista Pharmaceuticals had 4 more articles in the media than Journey Medical. MarketBeat recorded 6 mentions for KalVista Pharmaceuticals and 2 mentions for Journey Medical. KalVista Pharmaceuticals' average media sentiment score of 0.22 beat Journey Medical's score of -0.25 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KalVista Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Journey Medical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

KalVista Pharmaceuticals currently has a consensus price target of $24.83, suggesting a potential upside of 108.68%. Journey Medical has a consensus price target of $9.50, suggesting a potential upside of 33.80%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe KalVista Pharmaceuticals is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Journey Medical
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

KalVista Pharmaceuticals has a net margin of 0.00% compared to Journey Medical's net margin of -14.76%. Journey Medical's return on equity of -52.03% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
KalVista PharmaceuticalsN/A -104.25% -78.69%
Journey Medical -14.76%-52.03%-11.28%

Journey Medical has higher revenue and earnings than KalVista Pharmaceuticals. Journey Medical is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KalVista PharmaceuticalsN/AN/A-$126.64M-$3.72-3.20
Journey Medical$56.13M2.95-$14.67M-$0.39-18.21

7.3% of Journey Medical shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

KalVista Pharmaceuticals and Journey Medical tied by winning 8 of the 16 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DERM vs. The Competition

MetricJourney MedicalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$165.40M$2.43B$5.56B$9.05B
Dividend YieldN/A1.78%5.24%3.99%
P/E Ratio-18.219.0227.6520.23
Price / Sales2.95680.43419.56119.26
Price / CashN/A21.7726.2128.59
Price / Book7.804.558.035.65
Net Income-$14.67M$31.26M$3.18B$249.15M
7 Day Performance-0.56%3.25%2.93%3.28%
1 Month Performance-3.92%3.46%1.72%3.95%
1 Year Performance36.28%0.77%34.39%20.98%

Journey Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DERM
Journey Medical
1.922 of 5 stars
$7.10
+0.9%
$9.50
+33.8%
+36.3%$165.40M$56.13M-18.2190Analyst Downgrade
KALV
KalVista Pharmaceuticals
4.1434 of 5 stars
$11.93
-1.8%
$24.83
+108.2%
+0.9%$604.04MN/A-3.21100Upcoming Earnings
EOLS
Evolus
3.6908 of 5 stars
$9.38
+1.1%
$23.75
+153.2%
-15.2%$598.33M$266.27M-10.54170Positive News
SANA
Sana Biotechnology
2.7581 of 5 stars
$2.60
-0.4%
$10.80
+315.4%
-37.2%$588.49MN/A-2.95380Analyst Forecast
Gap Up
High Trading Volume
UPB
Upstream Bio
N/A$10.72
-1.5%
$56.50
+427.1%
N/A$585.28M$2.37M0.0038
SAGE
Sage Therapeutics
3.222 of 5 stars
$9.30
flat
$8.93
-3.9%
-14.7%$582.37M$41.24M-1.60690
ALT
Altimmune
2.2023 of 5 stars
$6.99
-0.6%
$19.00
+171.8%
-28.1%$570.18M$20K-5.5550
TNGX
Tango Therapeutics
1.969 of 5 stars
$5.32
+3.1%
$12.20
+129.3%
-33.5%$559.31M$42.07M-4.3690Analyst Revision
KROS
Keros Therapeutics
4.0634 of 5 stars
$13.76
+2.0%
$30.56
+122.1%
-68.4%$547.90M$3.55M-76.44100
RLAY
Relay Therapeutics
2.7909 of 5 stars
$3.23
+1.3%
$17.67
+447.0%
-43.1%$546.91M$10.01M-1.45330Positive News
AUTL
Autolus Therapeutics
2.5424 of 5 stars
$2.21
+7.8%
$9.32
+321.7%
-31.3%$545.59M$10.12M-2.51330

Related Companies and Tools


This page (NASDAQ:DERM) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners